Who are SAB Biotherapeutics, Inc.'s main suppliers?

SAB Biotherapeutics, Inc. (SABSW) key suppliers include: Emergent BioSolutions Inc., Emergent BioSolutions Inc., Fortrea Holdings Inc., Fortrea Holdings Inc., Sanofi and 1 more. View the full supplier network at chainsifter.com/chain/SABSW.

Who are SAB Biotherapeutics, Inc.'s major customers?

SAB Biotherapeutics, Inc. (SABSW) key customers include: Biodexa Pharmaceuticals Plc, Emergent BioSolutions Inc., Emergent BioSolutions Inc., Sanofi, Sanofi. View the full customer network at chainsifter.com/chain/SABSW.

What sector is SAB Biotherapeutics, Inc. in?

SAB Biotherapeutics, Inc. (SABSW) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

SAB Biotherapeutics, Inc. Suppliers, Customers & Supply Chain (SABSW)

6Suppliers

5Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

SAB Biotherapeutics, Inc. (SABSW) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

12Total relationships

4Distinct source URLs

1High confidence

0.735Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

SAB Biotherapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
EBS	Emergent BioSolutions Inc.	72%	uld result in reduced production yields, lot failures, product defects, product delays, product recalls, product liability claims and other supply disruptions. Further, as product candidates advance …
EBS	Emergent BioSolutions Inc.	72%	Reciprocal relationship from EBS graph: Reciprocal relationship from SABSW graph: uld result in reduced production yields, lot failures, product defects, product delays, product recalls, product liab…
FTRE	Fortrea Holdings Inc.	72%	uted amounts within thirty (30) days after written notice; (iii) by either party for material breach, subject to a cure period of thirty (30) days (or up to ninety (90) days if diligently pursued); (…
FTRE	Fortrea Holdings Inc.	72%	Reciprocal relationship from FTRE graph: Reciprocal relationship from SABSW graph: uted amounts within thirty (30) days after written notice; (iii) by either party for material breach, subject to a c…
SNYNF	Sanofi	72%	ct pipeline and that may outperform or be more competitive than our products. For example, there are multiple products that may be competitive with SAB-142 for T1D such as animal-derived polyclonal b…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from SABSW graph: ct pipeline and that may outperform or be more competitive than our products. For example, there are multiple produ…

SAB Biotherapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
BDRX	Biodexa Pharmaceuticals Plc	72%	Reciprocal relationship from BDRX graph: Reciprocal relationship from SABSW graph: Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and…
EBS	Emergent BioSolutions Inc.	72%	gal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates: (i) the rules and regulations of the F…
EBS	Emergent BioSolutions Inc.	72%	Reciprocal relationship from EBS graph: Reciprocal relationship from SABSW graph: Reciprocal relationship from EBS graph: Reciprocal relationship from SABSW graph: Reciprocal relationship from EBS gr…
SNYNF	Sanofi	72%	ct pipeline and that may outperform or be more competitive than our products. For example, there are multiple products that may be competitive with SAB-142 for T1D such as animal-derived polyclonal b…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from SABSW graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SABSW graph: ct pipeline and that may outper…

SAB Biotherapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SABSW-DEBT-12350	Warrants outstanding: 0.01	90%	xbrl warrant detail from xbrl 2024-12-31.

SAB Biotherapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for SAB Biotherapeutics, Inc..

SAB Biotherapeutics, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for SAB Biotherapeutics, Inc..

SAB Biotherapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
SNYNF	Sanofi	100.00	1	['customer', 'supplier']
EBS	Emergent BioSolutions Inc.	100.00	1	['customer', 'supplier']
FTRE	Fortrea Holdings Inc.	100.00	1	['supplier']
BDRX	Biodexa Pharmaceuticals Plc	100.00	1	['customer']
CYTOF	Altamira Therapeutics Ltd.	50.00	2
CRVS	Corvus Pharmaceuticals, Inc.	50.00	2
ALXO	ALX Oncology Holdings Inc.	50.00	2
CBIO	Crescent Biopharma, Inc.	50.00	2
ANRO	Alto Neuroscience, Inc.	50.00	2
DNTH	Dianthus Therapeutics, Inc.	50.00	2
CCEP	Coca-Cola Europacific Partners PLC	50.00	2
DSGN	Design Therapeutics, Inc.	50.00	2
AZN	AstraZeneca PLC	50.00	2
CLDX	Celldex Therapeutics, Inc.	50.00	2
LGND	Ligand Pharmaceuticals Incorporated	50.00	2
CYTK	Cytokinetics, Incorporated	50.00	2
DBVTF	DBV TECHNOLOGIES	50.00	2
EDIT	Editas Medicine, Inc.	50.00	2
FULC	Fulcrum Therapeutics, Inc.	50.00	2
DYN	Dyne Therapeutics, Inc.	50.00	2

SAB Biotherapeutics, Inc. Supply Chain